Relmada Therapeutics, Inc. (RLMD)

NASDAQ: RLMD · IEX Real-Time Price · USD

4.160

+0.105 (2.59%)

At close: Jul 19, 2024, 4:30 PM

4.100

-0.060 (-1.44%)

Pre-market: Jul 22, 2024, 8:07 AM EDT

Relmada Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2015
Net Income	-94.3	-98.79	-157.04	-125.75	-59.46	-15.01	Upgrade
Depreciation & Amortization	0	0	0	0	0	0	Upgrade
Share-Based Compensation	40.75	43.81	44.19	40.49	20.78	3.17	Upgrade
Other Operating Activities	5.36	3.32	9.05	-6.62	10.87	-0.26	Upgrade
Operating Cash Flow	-48.19	-51.66	-103.8	-91.87	-27.81	-12.09	Upgrade
Change in Investments	20.51	50.45	19.73	-54.12	-34.45	-80.16	Upgrade
Investing Cash Flow	20.51	50.45	19.73	-54.12	-34.45	-80.16	Upgrade
Share Issuance / Repurchase	0.25	0	43.43	185.31	20.53	122.03	Upgrade
Debt Issued / Paid	0	0	0	0	-0.11	-0.37	Upgrade
Other Financing Activities	-0.12	-0.1	1.59	2.63	8.06	4.45	Upgrade
Financing Cash Flow	0.12	-0.1	45.02	187.94	28.47	126.11	Upgrade
Net Cash Flow	-27.56	-1.3	-39.05	41.95	-33.78	33.85	Upgrade
Free Cash Flow	-48.19	-51.66	-103.8	-91.87	-27.81	-12.09	Upgrade
Free Cash Flow Per Share	-1.60	-1.72	-3.50	-5.23	-1.78	-1.31	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).